Xarelto Lawsuit Plaintiffs Take Note Of New Controversies Surrounding Anticoagulant Drug

March 29, 2016 – – BloodThinnerHelp.com reports on new controversies surrounding blood-thinning drug Xarelto after,“…a document claimed that two major pharmaceutical companies may have misled a medical journal by leaving out some critical data on their drug,” according to a recent online article from Business Insider.

The drug amongst all of this controversy is anticoagulant Xarelto, produced by manufacturers Bayer and Johnson & Johnson subsidiary Janssen Pharmaceuticals. Xarelto was approved by the U.S. Food and Drug Administration in 2011 to treat patients recovering from hip and knee replacement surgeries, as well as those with deep vein thrombosis, pulmonary embolism, and atrial fibrillation. The new-generation blood thinner has been very popular since its launch to market, in fact, Business Insider reports that, “In 2015, Xarelto made about $1.8 billion in U.S. sales. But it’s also the subject of more than 5,000 lawsuits, 500 of which involve patient deaths.”

Katie Thomas of The New York Times reportedly discovered a footnote within a federal legal briefing that indicated the possibility of evidence showing that Xarelto’s manufacturers (Johnson & Johnson and Bayer) potentially excluded critically important data which was requested by a peer reviewer at the prestigious New England Journal of Medicine. Business Insider notes that, “That data could have given the reviewer an idea of how the blood readings from one device compare to another.”

This newly discovered controversy follows months of public concern regarding a clinical trial test which took place to determine the effectiveness of Xarelto when compared to traditional blood thinner warfarin. It was discovered post-study that one of the blood-clot testing devices used during the trial had been recalled and may have falsely impacted the testing results.

It has been reported that at this time, both the U.S. Food and Drug Administration and the European Medicine Agency are investigating this faulty blood-testing device to determine whether it may have led to a premature approval for Xarelto.

Thousands of plaintiffs currently involved in Xarelto lawsuits from across the nation are anxiously awaiting the findings of these investigations. Those involved predict that Xarelto lawsuit numbers will only continue to grow in the meantime. As time goes on, Attorney Joseph Osborne is working to do his part to help ensure that anyone who used Xarelto and feels that they suffered from the drug will be given the opportunity to fully explore their legal rights. These patients may be entitled to legal action and significant compensation. To better help those wishing to learn more, Attorney Osborne is currently offering free legal consultations to affected parties.

To request additional information concerning Xarelto lawsuits, or to ask questions, please call Attorney Osborne at (866) 425-8902.

###

Contact BloodThinnerHelp.com:

Joseph Osborne
866-425-8902
Mizner Park
433 Plaza Real Blvd., Ste. 271
Boca Raton, FL 33432

ReleaseID: 60008958